We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Stockal+Disclaimer.pdf
9 own
5 watching
Current Price
$10.6
$0.03
(0.28%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
382.52M
52-Week High
18.24000
52-Week Low
8.20000
Average Volume
0.16M
Dividend Yield
--
P/E Ratio
--
Market Capitalization382.52M52-Week High18.2400052-Week Low8.20000Average Volume0.16MDividend Yield--P/E Ratio--What does the Stockal+Disclaimer.pdf do?
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. --- We were incorporated in October 2019 under the laws of the State of Delaware. Our principal executive offices are located at 139 Main Street, Cambridge, MA 02142, and our telephone number is (339) 217-0162. We have one subsidiary located in Belgium, iTeos Belgium SA, which was incorporated in August 2011 under the laws of Belgium. Our website address is www.iteostherapeutics.com.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
1 year ago
HC Wainwright reaffirmed their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS Get Rating) in a report published on Friday morning, Benzinga reports. The brokerage currently has a $54.00 price objective on the stock. Several other analysts have also recently issued reports on the stock. ...
Globe Newswire
1 year ago
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel ...
Ticker Report
1 year ago
iTeos Therapeutics, Inc. (NASDAQ:ITOS Get Rating) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,870,000 shares, a decrease of 7.4% from the October 31st total of 2,020,000 shares. Currently, 6.5% of the shares...
Ticker Report
1 year ago
iTeos Therapeutics, Inc. (NASDAQ:ITOS Get Rating) Director David Hallal sold 1,171 shares of the companys stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $19.51, for a total value of $22,846.21. The sale was disclosed in a legal filing with ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
Can Indians buy Stockal+Disclaimer.pdf shares?
How can I buy Stockal+Disclaimer.pdf shares from India?
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
What is today’s traded volume of Stockal+Disclaimer.pdf?
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
Current Price
$10.6
$0.03
(0.28%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.